Abstract: Imarikiren hydrochloride (TAK-272/SCO-272) is a novel direct renin inhibitor with potential indications for cardiovascular and renal diseases. This phase I study evaluated the pharmacokinetics, pharmacodynamics and safety of a single oral administration of imarikiren in healthy Japanese male subjects. The Dose-Ascending part (double-blind, placebo-controlled, parallel-group design; n = 60) comprised six steps from 5 to 200 mg (n = 8 for imarikiren and n = 2 for placebo per step). The Food Effect part (n = 12) was an open-label, 2 9 2 crossover design with a dose of 50 mg to evaluate the effect of food on the pharmacokinetics and safety of imarikiren. There was a generally linear relationship between dose and area under the plasma concentration-time curve (0 to infinity) or maximum plasma concentration of imarikiren. Food had no clinically significant effect on the exposure of imarikiren. Inhibition of plasma renin activity was rapid and lasted up to 24 hr at all doses. Plasma active renin concentration increased, reaching a maximum at approximately 6 hr, in a nearly dose-dependent manner. Across both study parts, the number of subjects with treatment-emergent adverse events ranged from 0 to 3 per group with no dependency on dose. All treatment-emergent adverse events except two were mild in intensity; there were no serious adverse events or deaths. Single oral administration of imarikiren from 5 to 200 mg was safe and well tolerated. These findings suggest that further clinical development of a once-daily imarikiren regimen is warranted.
The renin-angiotensin system (RAS) plays a crucial role in vascular, renal and cardiac physiology through regulation of arterial pressure, tissue perfusion and extracellular volume [1] .
Activation of the RAS is central to many common pathological conditions, such as renal disease, hypertension and heart failure. Drugs targeting the RAS include angiotensin I (AI)-converting enzyme (ACE) inhibitors and angiotensin II (AII) receptor blockers (ARBs), prescribed globally for the treatment of hypertension, diabetic nephropathy and heart disease. However, ACE inhibitors and ARBs likely do not inhibit the RAS completely, due to compensatory increases in plasma renin activity (PRA). Non-classical branches of the RAS, such as ACE-independent sources of AII or signalling by peptides other than AII through other receptors, may not be targeted by these therapies [1] .
Direct renin inhibitors act on renin, which is the rate-limiting enzyme that initiates the entire RAS; they are therefore expected to exert effects similar to or greater than ACE inhibitors or ARBs by inhibiting the whole RAS [1] . A direct renin inhibitor, aliskiren, has been approved for treatment of hypertension; however, it has low bioavailability and the maximum clinical dosage is limited due to gastrointestinal adverse events (diarrhoea) [1, 2] .
Imarikiren hydrochloride (TAK-272/SCO-272) is a novel direct renin inhibitor. In pre-clinical studies, it has demonstrated good bioavailability, strong inhibition of PRA and dosedependent hypotensive and systemic organ-protecting effects that were more potent than those of aliskiren [3] . This first-inhuman phase I study was conducted to evaluate the pharmacokinetics, pharmacodynamics and safety of a single oral administration of imarikiren in healthy adult male subjects.
Materials and Methods
The primary objective of this study was to evaluate the pharmacokinetics and safety of a single oral administration of imarikiren by a placebo-controlled, double-blind, group comparison method. The secondary objective was to evaluate the effect of food on the pharmacokinetics and safety of a single oral administration of imarikiren.
This study was conducted in healthy Japanese adult male volunteers. Key inclusion criteria included age 20-35 years (inclusive) and weight ≥50 kg with body mass index ≥18.5 kg/m 2 and <25.0 kg/m 2 .
Key exclusion criteria included present history of sustained (nonaccidental) electrolyte abnormalities; pulse rate of <45 beats per min. or ≥100 beats per min. at screening; systolic blood pressure of <90 mmHg with suspected hypotension from multiple findings (light-headedness, facial pallor and cold sweat) based on physical examinations at screening and immediately before treatment administration; and ≥1 of the following abnormal electrocardiogram findings at screening: second-or third-degree atrioventricular block, QRS duration >120 msec., QTc interval corrected for heart rate by Fridericia's equation (QTcF) >450 msec., PR interval >240 msec. or other electrocardiogram abnormalities considered to be clinically significant by the investigator or subinvestigator. All subjects provided written informed consent.
This phase I study consisted of two parts: a Dose-Ascending part and a Food Effect part.
The Dose-Ascending part evaluated the pharmacokinetics, pharmacodynamics and safety of a single oral administration of imarikiren. It Author for correspondence: Emiko Koumura, Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, 1-1, Doshomachi 4-chome, Chuo-ku, Osaka, Japan, 540-8645 (e-mail emiko.koumura@takeda.com).
employed a double-blind, placebo-controlled, parallel-group design and comprised seven steps: Steps 1-6 (10, 25, 50, 100, 200 and 400 mg) and Step 8 (5 mg). Ten distinct subjects (eight subjects in the imarikiren group and two in the placebo group) were planned to participate in each step. A staggered study design was used for Steps 1-6. One subject each was randomized to and received imarikiren or placebo. When the safety was confirmed in these two subjects in terms of adverse events, vital signs, weight, electrocardiogram findings (including digital 12-lead Holter electrocardiogram [continuation] test) and clinical laboratory test results up to 24 hr after administration, the remaining eight randomized subjects (imarikiren, n = 7; placebo, n = 1) received the investigational drug.
Subjects were hospitalized for days À2 to 4. Each subject received a single oral administration of imarikiren or placebo tablets in the morning of day 1. The subjects were placed under close surveillance by the investigator in the investigational site until 72 hr after administration (day 4) and discharged after confirming the safety by medical checks on day 4. On day 8, the subjects visited the investigational site for the final evaluation of safety by end-of-period examinations.
In Steps 1-6, whether to step-up administration was decided by the sponsor upon discussion with the investigator after review of the pharmacokinetic data up to 24 hr after administration and the safety data up to 168 hr after administration in the preceding step; therefore, there was an interval of at least 8 days between the steps. Step 8 (5 mg) was added during the study because the results of Step 1 (10 mg) showed higher plasma concentrations and stronger inhibition of PRA than expected from the pre-clinical study results.
The Food Effect part evaluated the effects of food on the pharmacokinetics, pharmacodynamics and safety of imarikiren. It was a onestep (Step 7), open-label, two-treatment, crossover study comprising two periods (Periods 1 and 2) with an interval of at least 8 days between periods. The Food Effect part was initiated following comprehensive review of the safety in Steps 1-5. Six subjects each (12 total) were randomized to receive imarikiren under fasted then fed conditions (Sequence A) or vice versa (Sequence B). Pharmacokinetics and pharmacodynamics of imarikiren 50 mg under fasted and fed conditions were compared. The subjects were hospitalized from days À1 to 4. The main schedules of hospitalization, discharge and visits were the same as those of the Dose-Ascending part, except for the digital 12-lead Holter electrocardiogram (continuation) test, which was not performed.
The sample sizes for each part of the study were not based on statistical considerations.
The institutional review board of the investigational site reviewed and approved the clinical study protocol. The study was conducted in accordance with the Declaration of Helsinki.
Subjects in the Dose-Ascending part were to receive the investigational drug with 200 mL of water after fasting for >10 hr. Any food and drinks were prohibited from 2 hr prior to administration until 4 hr after administration (until lunch), except for 200 mL of water at administration.
In the Food Effect part, subjects in both Sequence A and Sequence B received imarikiren 50 mg. In the case of administration under the fasted condition, subjects were to receive the investigational drug with 200 mL water after fasting for more than 10 hr. In the case of administration under the fed condition, subjects were to receive the investigational drug with 200 mL of water 30 min. after starting breakfast (breakfast was to take about 10 min.). Any food and drinks were prohibited from 2 hr prior to administration until 4 hr after administration (until lunch), except for breakfast (including drinks) in the case of administration under fed condition, and 200 mL of water at the time of administration.
Subjects in both parts took only the prescribed meals during hospitalization and took no other foods. The same meal food content (caloric intake and energy allocation) was served during each step. Food Table 1 .
Demographics and baseline characteristics. In Sequence A, subjects received imarikiren hydrochloride first under fasted and then under fed conditions. 2 In Sequence B, subjects received imarikiren hydrochloride first under fed and then under fasted conditions. containing grapefruit juice or pulp, caffeine and alcohol was prohibited. On days À2, À1 and 1 of the Dose-Ascending part, the total lipid intake was to be <20%. Under the fed condition in the Food Effect part, subjects were to receive the investigational drug 30 min. after starting breakfast (20.5 g of protein, 94.8 g of carbohydrates, 19.9 g of fat; total calories, 655 kcal). The plasma concentration, pharmacokinetic parameters and urinary concentration of imarikiren and its major metabolite, M-I, were evaluated by Sekisui Medical Company Limited using high-performance liquid chromatography-tandem mass spectrometry. The calibration ranges for the plasma assay were 0.5-500 ng/mL for both imarikiren and M-I; calibration ranges for the urine assay were 20-20,000 ng/mL for both imarikiren and M-I. Urinary excretion ratio was calculated by multiplying urinal concentration by urine volume of each sampling fraction. Pharmacodynamic end-points, including PRA, plasma active renin concentration (PRC), plasma AI concentration, plasma AII concentration and plasma aldosterone concentration (PAC), were evaluated by Mitsubishi Chemical Medience Company Limited using a radioimmunoassay with lower limit of quantification of 0.1 ng/mL/hr for PRA, 2.0 pg/mL for PRC, 100 pg/mL for AI, 4 pg/mL for AII and 7 pg/mL for PAC. The inhibition rate of PRA was calculated by a following equation: PRA inhibition rate = (PRA at 1 hr before administration À PRA at each time-point)/(PRA at 1 hr before administration) 9 100 (%).
Blood sampling for pharmacokinetic analyses was performed at 1 hr before and 0.5, 1, 1. Pharmacokinetic parameters were estimated from plasma concentration-time profiles for each analyte using WinNonlin (Pharsight, St. Louis, MO, USA) by non-compartmental analysis. Actual sampling times were used for estimation of these pharmacokinetic parameters. For the Dose-Ascending part, scatter plots of pharmacokinetic parameters versus dose were constructed, and the relationship between these parameters and dose was evaluated by a power regression model (Y = A*(Dose) b ). For the Food Effect part, two-sided 90% confidence intervals (CIs) of the difference between the administration condition (fed -fasted) were calculated, based on analysis of variance with natural log-transformed pharmacokinetic parameters of imarikiren as dependent variables and administration condition, sequence and period as fixed effects.
To evaluate the relationship between QT/QTc interval and plasma concentration, scatter plots of plasma concentration of imarikiren or M-I versus change from time-matched baseline in QT/QTc interval were constructed. Change from time-matched baseline in QT/QTc interval and the two-sided 90% CI at the median maximum serum concentration (C max ) of imarikiren or M-I were also estimated, based on a linear mixed-effect model with change from time-matched baseline in QT/QTc interval as dependent variables, plasma concentration of imarikiren or M-I as an independent variable and subject as a random effect.
Descriptive statistics, statistical analysis and data plot were performed with SAS version 9.2.
Results
A total of 236 subjects were screened. A total of 72 subjects were randomized and received the investigational drug, 70 of whom completed the study. Two subjects in the Food Effect part were withdrawn from the study, one because of an adverse event (conjunctivitis bacterial requiring treatment) and one for a major protocol deviation (taking alcohol and caffeine prior to investigational drug administration).
Step 6 of the Dose-Ascending part (400 mg) was not conducted because of the possibility that C max and area under the In the Dose-Ascending part, the plasma pharmacokinetics, pharmacodynamics and safety analysis sets included all 60 subjects, while the urine pharmacokinetics analysis set included 57 subjects; three subjects (one each in the placebo, 5-mg and 200-mg groups) were excluded because of inadequate urine collection.
In the Food Effect part, the safety analysis set included all 12 subjects, and the plasma pharmacokinetics, urine pharmacokinetics and pharmacodynamics analysis sets consisted of 10 subjects; two subjects from Sequence A were excluded; both were withdrawn from the study, and one had inadequate diet and drink control.
Baseline characteristics are shown in table 1. The mean age of subjects who received the investigational drug by dose group and administration condition ranged from 23.0 to 28.2 years. The mean weight of subjects ranged from 60. (Table S1 ). The urinary excretion ratio up to 72 hr after administration ranged from 13% to 17% (table 2) . Imarikiren was the main compound detected in plasma; the AUC 0-inf of M-I was ≤3% that of imarikiren.
Descriptive statistics for pharmacokinetic parameters of imarikiren following a single oral administration of imarikiren 50 mg under fed and fasted conditions are shown in table 2. The point estimate (two-sided 90% CI) of the ratio (fed/fasted) of geometric least-squares means of AUC 0-inf of imarikiren under fed versus fasted conditions was 0.950 (0.839-1.075). The 90% CI for AUC 0-inf met the bioequivalence criteria (0.80-1.25) [4, 5] . The point estimate (twosided 90% CI) of the ratio of geometric least-squares means of C max of imarikiren was 0.865 (0.697-1.073), indicating an approximately 14% decrease in C max under the fed condition versus the fasted condition. The urinary excretion ratio of imarikiren was similar between fasted and fed conditions. The analysis set for urinary excretion ratio (Fe) and renal clearance (CLr) included seven subjects in the 5-mg and 200-mg groups.
There was little relationship between plasma concentrations of imarikiren and the changes from time-matched baseline in QTcF intervals (slope for the linear mixed model: À0.0010 msec./ng/mL; fig. 2 ). Similar tendencies were observed for other QT/QTc intervals.
Arithmetic mean time profiles of the inhibition of PRA through 168 and 24 hr after single oral administration are shown in fig. 3A . Imarikiren administration rapidly inhibited PRA at all doses. Inhibition of PRA was observed up to 24 hr after imarikiren administration at all doses, with inhibition lasting longer with higher doses.
Arithmetic mean time profiles of change from baseline in PRC through 168 and 24 hr after single oral administration are shown in fig. 3B . PRC increased after a single oral administration of imarikiren and reached maximum around 6 hr after administration. The increase was nearly dose-dependent: the peak PRC was similar between 50 mg and 200 mg of imarikiren.
Other biomarkers of the RAS (AI, AII and PAC) rapidly decreased after imarikiren administration, with the exception of AII in the 10-mg group. There was no obvious doseresponse relationship.
Treatment-emergent adverse events were reported in the placebo, 10-mg, 25-mg, 100-mg and 200-mg groups in the Dose-Ascending part and under both fed and fasted conditions in the Food Effect part (table 3) ; the number of subjects reporting treatment-emergent adverse events by dose group and administration condition ranged from 0 to 3. Headache and epistaxis were the only treatment-emergent adverse events that occurred in more than one subject (n = 2 each). There was no dose-dependent increase in the frequency of adverse events. In the Food Effect part, treatment-emergent adverse events were reported in 25.0% of the subjects under the fasted condition and 10.0% of subjects under the fed condition. All treatment-emergent adverse events were mild in intensity, with the exception of moderate tooth fracture in the 100-mg group in the Dose-Ascending part (one subject) and moderate dizziness postural under the fed condition in the Food Effect part (one subject). Six treatment-emergent adverse events were considered to be related to the investigational drug: epistaxis (10-mg group), blood pressure decreased (100-mg group) and headache (200-mg group) in the Dose-Ascending part (one subject each); and headache (fasted), dizziness postural (fed) and pallor (fed) in the Food Effect part (one subject each). There were no serious treatment-emergent adverse events and no deaths during the study. The outcomes of all treatmentemergent adverse events except for one event (moderate tooth fracture) were considered recovered/resolved. One subject (fasted) discontinued the study due to a treatmentemergent adverse event (mild conjunctivitis bacterial requiring treatment).
No clinically meaningful changes were observed in the mean values of clinical laboratory tests. Three treatmentemergent adverse events related to clinical laboratory tests (aspartate aminotransferase increased, blood creatine phosphokinase increased and blood glucose increased) were reported, but were all considered to be unrelated to the investigational drug, were mild in intensity and recovered/resolved. No obvious changes were observed in the mean values of vital signs and weight, except for decreases in blood pressure that were not clinically significant. One event of blood pressure decreased was reported as a treatment-emergent adverse event and was considered to be related to the investigational drug and recovered/resolved.
Few subjects had clinically significant prolongation in PR interval (PR interval >200 msec. was observed in 1 patient [100 mg]) or QTcF interval (QTcF interval >450 msec. was observed in 1 patient [25 mg]; QTcF interval >480 msec. was not observed) after investigational drug administration. There were no dose-dependent increases in number of subjects with clinically significant prolongation or changes in these parameters. There were no clinically significant changes in QT intervals, QTcB intervals or QRS durations, and no electrocardiogram-related treatment-related adverse events were reported.
Discussion
This study was the first to evaluate the pharmacokinetics, pharmacodynamics and safety of imarikiren in human subjects. Imarikiren was rapidly absorbed after a single oral administration. Imarikiren was the main compound detected in plasma. AUC 0-inf and C max of imarikiren generally showed dose proportionality at the dose range between 5 mg and 200 mg of imarikiren. No clinically significant food effects were observed. Therefore, imarikiren can be administered with or without food.
Following single oral administration of imarikiren, rapid inhibition of PRA was observed. This inhibition lasted longer with higher doses and lasted at least 24 hr at all doses. Following single oral administration of imarikiren, a rapid increase in PRC was observed and PRC reached a maximum around 6 hr after administration. The increase was nearly dose-dependent, but the peak PRC was at the same level at the dose range between 50 and 200 mg. The concomitant inhibition of PRA and increase in PRC suggest that inhibition of PRA causes an increase in renin secretion. However, PRC increased with higher doses of imarikiren, despite apparently complete inhibition of imarikiren with all doses; this may indicate that complete inhibition of renin activity at the site of renin secretion did not occur at doses <50 mg. Renin was either completely inhibited at the site of its secretion or the maximum effect on renin secretion was reached, only at doses >50 mg.
Single oral administration of imarikiren (dosing range, 5-200 mg) was generally safe and well tolerated, with no dose-limiting toxicity. There was a low frequency of treatmentemergent adverse events reported that were mild to moderate in intensity, did not show dose-dependent increase and were not affected by food intake. No serious treatment-emergent adverse event or death was reported during this study. In addition, the effect of imarikiren on QT/QTc interval was investigated in a concentration-QT analysis, which is an important component of the totality of evidence assessment of the risk of QT prolongation [6] . The plasma concentration of imarikiren, which showed an increase proportional to imarikiren dose, did not show a clinical effect on QT/QTc interval in the case of single oral administration of imarikiren at doses of 5-200 mg based on the results from the linear mixed-model analysis. In addition, there were no clinically significant changes in QT, QTcB, PR or QRS intervals.
Mean values of each haematological test did not change remarkably at any doses or under any conditions, and no treatment-emergent adverse events related to haematological test were reported, although shifts in haematology results from normal at baseline to low or high after administration were observed in a few subjects. The mean (S.D.) platelet counts and shifts in platelet counts are presented in Tables S2 and  S3, respectively. Renin is the rate-limiting enzyme of the entire RAS; thus, direct renin inhibitors are expected to exert effects similar to or potentially even greater than ACE inhibitors or ARBs. This study supports direct renin inhibition as a method of targeting the RAS, as previously demonstrated by aliskiren, the only commercially available direct renin inhibitor to date. In an in vitro test, imarikiren and its metabolite demonstrated strong inhibition of PRA in humans, with IC 50 of 0.21 and 0.43 nM, respectively, similar to that of aliskiren (0.16 nM). The 13%-17% urine excretion of imarikiren suggests improved bioavailability compared with aliskiren, which has a bioavailability of approximately 2.5% [7] . In addition, imarikiren showed a negligible food effect, while an 85% reduction in C max and 71% reduction in AUC are observed when imarikiren is taken with food [7] . In contrast to aliskiren, imarikiren strongly inhibited PRA in humans, which is attributable to the good pharmacokinetics profile and slow disassociation [8, 9] . In addition, no notable gastrointestinal adverse events were observed with any imarikiren dose in this study. The study demonstrates the utility of including electrocardiogram evaluation using Holter electrocardiogram to address cardiac effects early in the clinical development programme. The pharmacokinetic, pharmacodynamic and safety results of this study suggest that further development of once-daily oral administration of imarikiren is warranted. Limitations of the current study are that it included a small number of young, healthy, Japanese male subjects and that it only provides single-dose data. To understand the effects of chronic use of imarikiren in a broader population, further evaluation is needed. In fact, additional studies in other populations, including elderly individuals [8] , patients with renal or hepatic impairment (NCT02367872) and patients with type 2 diabetes mellitus and microalbuminuria (NCT02332824), have been conducted.
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